Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities for personalized medicine. In this study, we aim to illustrate the implementation of NGS-based liquid biopsy in clinical practice for the detection of somatic alterations in selected genes. Our work is...
Main Authors: | Elisabetta Zulato, Valeria Tosello, Giorgia Nardo, Laura Bonanno, Paola Del Bianco, Stefano Indraccolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/8/1468 |
Similar Items
-
BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings
by: Pancrazzi Pancrazzi, et al.
Published: (2023-09-01) -
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01) -
Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity
by: Maxim Ivanov, et al.
Published: (2019-03-01) -
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
by: Loc Carlo Bao, et al.
Published: (2024-03-01) -
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
by: Martyna Filipska, et al.
Published: (2021-06-01)